Literature DB >> 25974616

Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill".

S Srinivasan1,2,3,4, J C Florez3,5,6,4.   

Abstract

Type 2 diabetes has become an enormous public health burden, making diabetes prevention a pressing issue. While lifestyle modification is the most effective preventive strategy, it is resource-intensive and not universally sustainable. We review the evidence on pharmacological options for diabetes prevention, in search of a medication that is efficacious, easy to adhere to, well tolerated, and cost-effective. With the exception of metformin, most other drugs have either limited efficacy or costly side effects.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25974616      PMCID： PMC4511706          DOI： 10.1002/cpt.146

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  35 in total

1.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

Authors:  A Ramachandran; C Snehalatha; S Mary; B Mukesh; A D Bhaskar; V Vijay
Journal:  Diabetologia       Date:  2006-01-04       Impact factor: 10.122

2.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

3.  Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.

Authors:  Robert Ratner; Ronald Goldberg; Steven Haffner; Santica Marcovina; Trevor Orchard; Sarah Fowler; Marinella Temprosa
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

4.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

Authors:  Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski
Journal:  N Engl J Med       Date:  2013-06-24       Impact factor: 91.245

5.  Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program.

Authors: 
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

6.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.

Authors:  James P Boyle; Theodore J Thompson; Edward W Gregg; Lawrence E Barker; David F Williamson
Journal:  Popul Health Metr       Date:  2010-10-22

7.  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.

Authors:  Ryuzo Kawamori; Naoko Tajima; Yasuhiko Iwamoto; Atsunori Kashiwagi; Kazuaki Shimamoto; Kohei Kaku
Journal:  Lancet       Date:  2009-04-22       Impact factor: 79.321

8.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

9.  Incidence of diabetes following ramipril or rosiglitazone withdrawal.

Authors: 
Journal:  Diabetes Care       Date:  2011-04-22       Impact factor: 19.112

10.  Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

Authors:  Christine Clar; James Alexander Gill; Rachel Court; Norman Waugh
Journal:  BMJ Open       Date:  2012-10-18       Impact factor: 2.692
View more
  4 in total

1.  Piperine's mitigation of obesity and diabetes can be explained by its up-regulation of the metabolic rate of resting muscle.

Authors:  Leonardo Nogara; Nariman Naber; Edward Pate; Marcella Canton; Carlo Reggiani; Roger Cooke
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

Review 2.  Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes.

Authors:  Jason Flannick; Stefan Johansson; Pål R Njølstad
Journal:  Nat Rev Endocrinol       Date:  2016-04-15       Impact factor: 43.330

3.  The variability in beta-cell function in placebo-treated subjects with type 2 diabetes: application of the weight-HbA1c-insulin-glucose (WHIG) model.

Authors:  Janna K Duong; Willem de Winter; Steve Choy; Nele Plock; Himanshu Naik; Walter Krauwinkel; Sandra A G Visser; Katia M Verhamme; Miriam C Sturkenboom; B H Stricker; Meindert Danhof
Journal:  Br J Clin Pharmacol       Date:  2016-11-17       Impact factor: 4.335

Review 4.  Pancreatic β Cell Mass Death.

Authors:  Husnia I Marrif; Salma I Al-Sunousi
Journal:  Front Pharmacol       Date:  2016-04-06       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.